Tackling metabolic disorders with non-coding RNAs
Resalis Therapeutics is developing a non-coding RNA-based therapeutic approach to achieve long-lasting and disease-modifying effects in metabolic disorders.
RES-010, a non-coding RNA drug candidate designed to treat metabolic diseases.
We applied our deep understanding of metabolic diseases and the ncRNA modality to develop our lead candidate RES-010. We are advancing RES-010 toward clinical evaluation initially in obesity and fatty liver disease.
Meet our CEO Alessandro Toniolo and the Resalis team at:
FEBRUARY 6-9, 2023
Bio CEO, New York
MARCH 20-22, 2023
BIO-Europe Spring, Basel
MAY 3-4, 2023
LSX World Congress, London
JUNE 5-8, 2023
BIO International Convention, Boston